Source link <\/a><\/p>\n","protected":false},"excerpt":{"rendered":"October 14, 2026 3 min read
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on . “
data-action=”subscribe”>
Subscribe
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Back to Healio Key takeaways: DNA methylation test detected Barrett\u2019s esophagus with 90% sensitivity and 86% specificity, rising to 99% for long-segment disease. The test reached 100% sensitivity for dysplasia and esophageal adenocarcinoma. NASHVILLE, Tenn. \u2014 A novel DNA methylation test using the EndoSign capsule-sponge detected Barrett\u2019s esophagus with 90% sensitivity and 86% specificity, excelling in longer segments and patients with dysplasia or esophageal adenocarcinoma. Late-breaking clinical trial data presented at ACG Annual Scientific Meeting suggest that this minimally invasive approach with Cyted Health\u2019s biomarker test could expand screening for at-risk individuals and help reduce esophageal adenocarcinoma mortality through earlier detection.
Nicholas J. Shaheen, MD, MPH, MACG, speaks at the podium during ACG Annual Scientific Meeting.\u00a0Photo by: Robert Stott.
\u201cNinety percent of patients with Barrett\u2019s esophagus are undiagnosed right now,\u201d Marcel Gehrung, PhD, cofounder and CEO of Cyted Health, told Healio. \u201cIn the U.S., we have around 30 to 32 million people that \u2014 according to the ACG guideline \u2014 have risk factors that might make them eligible for endoscopic or non-endoscopic screening. With 90% being undiagnosed, we have to ask ourselves: Are we scoping the right patients at the right time to pick up those patients with Barrett\u2019s esophagus who are at increased risk for developing esophageal adenocarcinoma?\u201d In the DETECT-ME trial, Nicholas J. Shaheen, MD, MPH, MACG, senior associate dean for clinical research at University of North Carolina School of Medicine, and colleagues prospectively evaluated the accuracy, safety and tolerability of the DNA methylation biomarker panel paired with the EndoSign device. The multicenter study enrolled 324 patients across 18 sites, including individuals undergoing screening due to elevated risk and patients with an established diagnosis of BE undergoing surveillance or endoscopic eradication treatment. Shaheen and colleagues analyzed DNA methylation in EndoSign samples collected before esophagogastroduodenoscopy, examining 654 BE-associated regions and 1,561 reference regions to establish baseline methylation levels. The researchers used the Mann\u2013Whitney rank-sum test to compare methylation in BE-associated and reference regions, with higher scores signaling a stronger likelihood for BE. Test sensitivity and specificity for BE served as primary endpoints, alongside tolerability, safety and sensitivity by dysplasia grade and BE length. Of the 324 participants in the primary analysis, 181 had BE and 143 did not. The test identified 163 of 181 patients with BE, corresponding to a sensitivity of 90% (95% CI, 84%-94%). Among patients without BE, 123 of 143 tested negative, yielding a specificity of 86% (95% CI, 79%-91%). The test also demonstrated 100% sensitivity for dysplasia and esophageal adenocarcinoma, with sensitivity for BE increasing with segment length. The researchers reported a sensitivity of 82% for short-segment BE (95% CI, 73%-89%) and 99% for long-segment BE (95% CI, 94%-100%), with an 87% sensitivity for nondysplastic BE. Detection improved significantly with each 1 cm increase in BE segment length (OR = 3.68; 95% CI, 1.56-8.68). Sensitivity was found to be lower in the high-risk screening group than in patients with previously diagnosed BE (69% vs. 92%), a difference consistent with the shorter BE segments in the screening group. \u201cWith 100% sensitivity for dysplasia and neoplasia, this is a test that has an exceptional negative predictive value, which really means you can trust a negative result, while at the same time having a massively increased yield in endoscopy in the patients who have tested positive,\u201d Gehrung told Healio. Additionally, Shaheen and colleagues reported that sampling was successful in 95% of participants, with no reported device-related adverse events. The test was also well tolerated, with 82% of participants rating its tolerability as excellent and 81% noting they would undergo the test again. \u201cPerhaps next year, or even before that, we are hopeful that, because we\u2019re using a very extensive biomarker panel, not only will we be able to [determine] Barrett\u2019s yes\/no, but we will actually be able to differentiate the degree of dysplasia,\u201d Shaheen told attendees. \u201cNot ready for prime time yet but stay tuned.\u201d Shaheen also noted that rather than viewing this technology as a threat to their existing endoscopy practice, gastroenterologists should be leading its adoption. \u201cUltimately, we hope this will become a primary care test, and as such, we should be embracing this,\u201d Shaheen said. \u201cThis is actually going to increase our business \u2014 if we do it right \u2014 because 90% of these patients aren\u2019t getting screened anyway. You are going to be doing more endoscopy, but you\u2019re going to be doing endoscopy for patients who are high risk and have already had a positive test. So, we should be leading the charge here.\u201d For more information: Marcel Gehrung, PhD, can be reached at gastroenterology@healio.com. Published by: Sources\/Disclosures Source: Shaheen NJ, et al. A prospective, multicenter cohort study of a novel methylation biomarker panel using non-endoscopic cell collection to detect Barrett\u2019s esophagus \u2013 The DETECT-ME study. Presented at: ACG Annual Scientific Meeting; Oct 12-14, 2026; Nashville, Tenn. (hybrid meeting).
Disclosures:
Gehrung reports consulting\/advisory relationships, employment, leadership and ownership interests with Cyted Health and Medtronic. Please see the study for all other authors\u2019 relevant financial disclosures.
Ask a clinical question and tap into Healio AI’s knowledge base.
PubMed, enrolling\/recruiting trials, guidelines
Clinical Guidance, Healio CME, FDA news
Healio’s exclusive daily news coverage of clinical data
Learn more
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on . “
data-action=”subscribe”>
Subscribe
We were unable to process your request. Please try again later. If you continue to have this issue please contact<\/p>\n","protected":false},"author":1,"featured_media":4027,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-4026","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/drsoniafawad.com\/index.php?rest_route=\/wp\/v2\/posts\/4026","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/drsoniafawad.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/drsoniafawad.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/drsoniafawad.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/drsoniafawad.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=4026"}],"version-history":[{"count":0,"href":"https:\/\/drsoniafawad.com\/index.php?rest_route=\/wp\/v2\/posts\/4026\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/drsoniafawad.com\/index.php?rest_route=\/wp\/v2\/media\/4027"}],"wp:attachment":[{"href":"https:\/\/drsoniafawad.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=4026"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/drsoniafawad.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=4026"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/drsoniafawad.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=4026"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
![\"Healio](\"https:\/\/www.healio.com\/~\/media\/h5\/feature\/news\/publogos\/hgld\/healio_gastro.svg?la=en&h=40&w=152&hash=2C654A538F2E250F5183D42A89FE0EC0\")
\n <\/div>\n<\/p><\/div>\n<\/p><\/div>\n